Dyspareunia in Women: Updates in Mechanisms and Current/Novel Therapies
Purpose of Review
Dyspareunia could influence negatively the sexuality of pre- and postmenopausal women. Genital pain can be cause for disturbing sexual desire. We conducted a review to describe interventions to address dyspareunia.
We reviewed 64 articles, based on studies concerning definitions of dyspareunia, genital sexual pain, different causes in pre/postmenopausal women, physical examination, management by age groups, and current/novel therapies. Evidence was drawn from systematic reviews of randomized controlled trials, clinical controlled studies, and case-control-studies, and from non-systematic reviews.
All included studies showed a significant reduction of dyspareunia after specific treatment. Women who received hormonal or non-hormonal medication, or physical therapy, had a better quality of sexual life. Hormonal and physical therapies show faster efficacy than non-hormonal therapies. In addition, pharmacological, psychological, and sexological integrated therapies seem to be more effective than single treatments.
KeywordsDyspareunia Endometriosis Estrogen therapy Female sexual disorders Genital sexual pain Genitourinary syndrome Hormonal-non hormonal therapies Ospemifene
The authors wish to thank the Scientific Bureau of the University of Catania for language support.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.• Barbara G, Facchin F, Buggio L, Somigliana E, Berlanda N, Kustermann A, et al. What is known and unknown about the association between endometriosis and sexual functioning: a systematic review of the literature. Reprod Sci. 2017;24:1566–76 The ideal treatment for endometriosis-related sexual dysfunctions should be conducted by a multidisciplinary team composed of gynecologists, sexologists, and psychologists /psychotherapists. CrossRefGoogle Scholar
- 8.Faubion SS, Rullo JE. Sexual dysfunction in women: a practical approach. Am Fam Physician. 2015;92:281–8.Google Scholar
- 9.Seehusen DA, Baird DC, Bode DV. Dyspareunia in women. Am Fam Physician. 2014;90:465–70.Google Scholar
- 15.Winer AG, Chakiryan NH, Mooney RP, Verges D, Ghanaat M, Allaeei A, et al. Secondary pelvic congestion syndrome: description and radiographic diagnosis. Can J Urol. 2014;21:7365–8.Google Scholar
- 18.•• Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s sexual health and the North American Menopause Society. Menopause. 2014;21:1063–8 This study formally endorsed the new terminology--genitourinary syndrome of menopause (GSM) shared by the Boards of NAMS and ISSWSH. CrossRefGoogle Scholar
- 23.• Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause. 2016;23:47–54 This study shows the efficacy of local vaginal estriol use on postmenopausal women with sexual disorders. CrossRefGoogle Scholar
- 25.Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH. A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. J Women's Health (Larchmt). 2018;27:231–7.CrossRefGoogle Scholar
- 26.Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause. 2018;25:133–8.Google Scholar
- 36.Caruso S, Cianci S, Fava V, Rapisarda AMC, Cutello S, Cianci A. Vaginal health of postmenopausal women on nutraceutical containing equol. Menopause. 2018;25:430–5.Google Scholar
- 37.Roghaei MA, Tehrany HG, Taherian A, Koleini N. Effects of Letrozole compared with Danazol on patients with confirmed endometriosis: a randomized clinical trial. IJFS. 2010;4:67–72.Google Scholar
- 38.Neri M, Piras B, Paoletti AM, Vallerino V, Corda V, Ronchetti C, et al. Long-acting reversible contraception (LARC) with the intrauterine system with levonorgestrel (6 mcg/d): observational study on the acceptability, quality of life, and sexuality in Italian women. Gynecol Endocrinol. 2018;34:532–5.CrossRefGoogle Scholar
- 40.Yucel N, Baskent E, Karamustafaoglu Balci B, Goynumer G. The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis. Aust N Z J Obstet Gynaecol. 2018;58:560–3. https://doi.org/10.1111/ajo.12773.CrossRefGoogle Scholar
- 45.•• Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68–91 This study supports the use of several drugs for symptomatic endometriosis having similar magnitude of effect, in terms of pain relief, independently of the mechanism of action. CrossRefGoogle Scholar
- 46.Soe LH, Wurz GT, Kao CJ, DeGregorio MW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womans Health. 2013;5:605–11.Google Scholar
- 51.•• Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother. 2015;16:2703–14 This study highlights the treatment with Ospemifene of postmenopausal women having dyspareunia, particularly for those who have tried and failed over-the-counter options or do not want vaginal therapies. CrossRefGoogle Scholar
- 53.Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy and of the genitourinary syndrome of menopause. Menopause. 2016;23:243–56.CrossRefGoogle Scholar
- 55.Nappi RE, Benedetto C, Campolo F, Martella S, Tosti C, Cianci A, et al. Efficacy, tolerability and safety of a new medical device, Monurelle Biogel(®) vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age. Eur J Obstet Gynecol Reprod Biol. 2016;203:82–8.CrossRefGoogle Scholar
- 56.Stefano S, Stavros A, Candiani M. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol. 2015;27:504–8.Google Scholar
- 57.• Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause: a systematic review and meta-analysis. Maturitas. 2017;103:78–88 This study indicate that CO2-laser therapy may contribute to complete regression of dyspareunia and dryness and reestablishment of normal sexual function in postmenopausal women. CrossRefGoogle Scholar
- 58.Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FLA, Santiago LHS, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25:21–2.CrossRefGoogle Scholar